- Home
- CELC vs HSAI Comparison
CELC vs HSAI Comparison
Compare CELC & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELC | HSAI |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CELC | HSAI |
|---|---|---|
| Price | $100.40 | $21.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $100.13 | $31.58 |
| AVG Volume (30 Days) | 959.5K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $385,835,909.00 |
| Revenue This Year | N/A | $55.36 |
| Revenue Next Year | N/A | $46.30 |
| P/E Ratio | ★ N/A | $46.78 |
| Revenue Growth | N/A | ★ 43.17 |
| 52 Week Low | $7.58 | $10.01 |
| 52 Week High | $112.64 | $30.85 |
Technical Indicators
Market Signals| Indicator | CELC | HSAI |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 58.84 |
| Support Level | $100.00 | $19.94 |
| Resistance Level | $112.64 | $21.38 |
| Average True Range (ATR) | 5.00 | 0.82 |
| MACD | -1.28 | 0.45 |
| Stochastic Oscillator | 21.82 | 96.97 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.